eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) is a clinical-stage biopharmaceutical company focused on oncology, specifically developing therapies that target translational regulators — proteins that control how cancer cells produce the building blocks they need to proliferate. The company completed its business combination with Locust Walk Acquisition Corp., a blank-check vehicle sponsored by Locust Walk Partners, in 2021, bringing it to the public markets through the SPAC route. The June 2022 Form 8-K current report was filed while the company remained in its post-merger clinical-stage status, advancing its pipeline of eIF4F complex inhibitors targeting solid tumors. Investors and analysts tracking post-merger SPAC performance in the healthcare and life sciences sector can access full filing details, ownership data, and company timelines on SpacDesk — sign up today for comprehensive SPAC intelligence.